AbbVie pre-announces Q1 2026 earnings beat with a cautious outlook, citing concerns over post-Humira growth and biosimilar competition. Despite exceeding earnings expectations, the company's warning about future growth prospects has led to a bearish sentiment and a stock price decline of 2.79%.
0 Comments
Share your thoughts
Get the Stock Events App
Sign up for a Stock Events account to create your own watchlists and track your portfolio or dividends.
